» Articles » PMID: 37174670

Molecular and Functional Characterization of Different BrainSphere Models for Use in Neurotoxicity Testing on Microelectrode Arrays

Overview
Journal Cells
Publisher MDPI
Date 2023 May 13
PMID 37174670
Authors
Affiliations
Soon will be listed here.
Abstract

The currently accepted methods for neurotoxicity (NT) testing rely on animal studies. However, high costs and low testing throughput hinder their application for large numbers of chemicals. To overcome these limitations, in vitro methods are currently being developed based on human-induced pluripotent stem cells (hiPSC) that allow higher testing throughput at lower costs. We applied six different protocols to generate 3D BrainSphere models for acute NT evaluation. These include three different media for 2D neural induction and two media for subsequent 3D differentiation resulting in self-organized, organotypic neuron/astrocyte microtissues. All induction protocols yielded nearly 100% -positive hiPSC-derived neural progenitor cells (hiNPCs), though with different gene expression profiles concerning regional patterning. Moreover, gene expression and immunocytochemistry analyses revealed that the choice of media determines neural differentiation patterns. On the functional level, BrainSpheres exhibited different levels of electrical activity on microelectrode arrays (MEA). Spike sorting allowed BrainSphere functional characterization with the mixed cultures consisting of GABAergic, glutamatergic, dopaminergic, serotonergic, and cholinergic neurons. A test method for acute NT testing, the human multi-neurotransmitter receptor (hMNR) assay, was proposed to apply such MEA-based spike sorting. These models are promising tools not only in toxicology but also for drug development and disease modeling.

Citing Articles

A Multi-Electrode Array Platform for Modeling Epilepsy Using Human Pluripotent Stem Cell-Derived Brain Assembloids.

Pan T, Jaklic D, Vaid S, Lin G, VanHeyningen D, Dang L J Vis Exp. 2024; 211.

PMID: 39400160 PMC: 11730284. DOI: 10.3791/67396.


HiPSC-derived 3D neural models reveal neurodevelopmental pathomechanisms of the Cockayne Syndrome B.

Kapr J, Scharkin I, Ramachandran H, Westhoff P, Pollet M, Dangeleit S Cell Mol Life Sci. 2024; 81(1):368.

PMID: 39179905 PMC: 11343962. DOI: 10.1007/s00018-024-05406-w.


Rigor and reproducibility in human brain organoid research: Where we are and where we need to go.

Sandoval S, Cappuccio G, Kruth K, Osenberg S, Khalil S, Mendez-Albelo N Stem Cell Reports. 2024; 19(6):796-816.

PMID: 38759644 PMC: 11297560. DOI: 10.1016/j.stemcr.2024.04.008.


New approach methods to assess developmental and adult neurotoxicity for regulatory use: a PARC work package 5 project.

Tal T, Myhre O, Fritsche E, Ruegg J, Craenen K, Aiello-Holden K Front Toxicol. 2024; 6:1359507.

PMID: 38742231 PMC: 11089904. DOI: 10.3389/ftox.2024.1359507.


Advancing Endocrine Disruptors via In Vitro Evaluation: Recognizing the Significance of the Organization for Economic Co-Operation and Development and United States Environmental Protection Agency Guidelines, Embracing New Assessment Methods, and....

Fouyet S, Ferger M, Leproux P, Rat P, Dutot M Toxics. 2024; 12(3).

PMID: 38535916 PMC: 10974109. DOI: 10.3390/toxics12030183.


References
1.
Somel M, Liu X, Tang L, Yan Z, Hu H, Guo S . MicroRNA-driven developmental remodeling in the brain distinguishes humans from other primates. PLoS Biol. 2011; 9(12):e1001214. PMC: 3232219. DOI: 10.1371/journal.pbio.1001214. View

2.
Carmichael P, Baltazar M, Cable S, Cochrane S, Dent M, Li H . Ready for regulatory use: NAMs and NGRA for chemical safety assurance. ALTEX. 2022; 39(3):359–366. DOI: 10.14573/altex.2204281. View

3.
Logan S, Arzua T, Canfield S, Seminary E, Sison S, Ebert A . Studying Human Neurological Disorders Using Induced Pluripotent Stem Cells: From 2D Monolayer to 3D Organoid and Blood Brain Barrier Models. Compr Physiol. 2019; 9(2):565-611. PMC: 6705133. DOI: 10.1002/cphy.c180025. View

4.
Chambers S, Fasano C, Papapetrou E, Tomishima M, Sadelain M, Studer L . Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat Biotechnol. 2009; 27(3):275-80. PMC: 2756723. DOI: 10.1038/nbt.1529. View

5.
Toutain P, Ferran A, Bousquet-Melou A . Species differences in pharmacokinetics and pharmacodynamics. Handb Exp Pharmacol. 2010; (199):19-48. DOI: 10.1007/978-3-642-10324-7_2. View